BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Taiwan's startup Acer Medical debuts VeriSee AI-assisted screening solutions

31 March 2025 | News

Collaboration with Intel for AI-powered medical screening optimisations



Taiwan-based startup Acer Medical has recently launched its artificial intelligence (AI)-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration.

These innovative solutions will be showcased at the Malaysian Ophthalmology Society (MSO) Annual Congress, from 25 to 27 April, bringing cutting-edge AI screening technology to Malaysia's ophthalmic community.

In collaboration with Intel, Acer Medical is advancing AI-driven medical imaging by accelerating AI inferencing and optimizing resource use with OpenVINO technology running on Intel Core Ultra processors.

OpenVINO is an open-source software toolkit designed for optimizing and deploying deep learning models. It significantly reduces development time by streamlining code implementation, facilitates rapid scalability, and enhances the efficiency of AI solutions. This collaboration ensures that advanced medical AI solutions can be deployed across all levels of medical institutions to process color retinal images in real-time, thereby making the solution more accessible while enhancing diagnostic efficiency and accuracy.

According to data from the Malaysian Medical Device Authority (MDA), Malaysia has one of the highest diabetes prevalence rates in Southeast Asia. Diabetes affects 18.3% of adults aged 18 and above, meaning approximately one in five Malaysians is diagnosed with the disease. With an aging population, the incidence of diabetic complications, including diabetic retinopathy, is expected to rise.

Acer Medical collaborates with hospitals and clinics in Malaysia to evaluate AI-driven medical solutions, enhancing diagnostic accuracy and efficiency. The VeriSee AI ophthalmic screening software analyzes color fundus images within seconds, providing high-accuracy detection of diabetic retinopathy and age-related macular degeneration. AI screening technology improves medical efficiency, enabling faster diagnoses at primary care facilities and ensuring timely treatment recommendations.